Abstract:In the past century, noncommunicable diseases have surpassed infectious diseases as the principal cause of sickness and death, worldwide. Trillions of commensal microbes live in and on our body, and constitute the human microbiome. The vast majority of these microorganisms are maternally derived and live in the gut, where they perform functions essential to our health and survival, including: digesting food, activating certain drugs, producing short-chain fatty acids (which help to modulate gene expression by inhibiting the deacetylation of histone proteins), generating anti-inflammatory substances, and playing a fundamental role in the induction, training, and function of our immune system. Among the many roles the microbiome ultimately plays, it mitigates against untoward effects from our exposure to the environment by forming a biotic shield between us and the outside world. The importance of physical activity coupled with a balanced and healthy diet in the maintenance of our well-being has been recognized since antiquity. However, it is only recently that characterization of the host-microbiome intermetabolic and crosstalk pathways has come to the forefront in studying therapeutic design. As reviewed in this report, synthetic biology shows potential in developing microorganisms for correcting pathogenic dysbiosis (gut microbiota-host maladaptation), although this has yet to be proven. However, the development and use of small molecule drugs have a long and successful history in the clinic, with small molecule histone deacetylase inhibitors representing one relevant example already approved to treat cancer and other disorders. Moreover, preclinical research suggests that epigenetic treatment of neurological conditions holds significant promise. With the mouth being an extension of the digestive tract, it presents a readily accessible diagnostic site for the early detection of potential unhealthy pathogens resident in the gut. Taken together, the data outlined herein provide an encouraging roadmap toward important new medicines and companion diagnostic platforms in a wide range of therapeutic indications.

Decoding the diagnostic and therapeutic potential of microbiota using pan-body pan-disease microbiomics

Longitudinal profiling of the microbiome at four body sites reveals core stability and individualized dynamics during health and disease

Global Compositional and Functional States of the Human Gut Microbiome in Health and Disease

A rational approach for the targeted discovery and characterisation of microbiome-derived therapeutics

The Human Microbiota in Health and Disease

Microbiota in Health and Disease-Potential Clinical Applications

Unlocking the Potential of the Human Microbiome for Identifying Disease Diagnostic Biomarkers

Human Gut Microbiota: Toward an Ecology of Disease.

Genome-wide association study in 8,956 German individuals identifies influence of ABO histo-blood groups on gut microbiome

Large-scale association analyses identify host factors influencing human gut microbiome composition

Microbiota and Neurological Disorders: A Gut Feeling

Evaluation of gut microbiota predictive potential associated with phenotypic characteristics to identify multifactorial diseases

Profiling the Human Intestinal Environment under Physiological Conditions.

Exploring the Human Microbiome: The Potential Future Role of Next-Generation Sequencing in Disease Diagnosis and Treatment

Pathophysiological and Clinical Potential of Human Microbiome: Microbe-based Therapeutic Insights

FROM MICROBIOME TO METABOLOME

Microbe-host interplay in atopic dermatitis and psoriasis

Microbiome risk profiles as biomarkers for inflammatory and metabolic disorders

Strain-level Dissection of the Contribution of the Gut Microbiome to Human Metabolic Disease

Gut microbiome-host interactions in health and disease

Bioinformatics and machine learning in gastrointestinal microbiome research and clinical application